Skip to main content
. 2018 Nov 2;119(10):1233–1243. doi: 10.1038/s41416-018-0286-4

Fig. 2.

Fig. 2

Moderate baseline levels of pRAD50(S635) across different cancer indications. Prevalence of pRAD50(Ser635) protein levels in a Gastric cancer; b triple negative breast cancer (TNBC); c glioblastoma-multiforme (GBM); d Colorectal cancer tumours (CRC). Data is given as the number of samples that fall within an expression bin of pRAD50(Ser635) positivity. e Percentage of pRAD50(Ser635) expression in matched primary CRC and liver metastatic tumours. f Example images of pRAD50(Ser635) IHC staining in each cancer indication that was pathology scored to generate the above data. Scale bars: 100 µm